title: alpha-glucosidase (CHO) (Genzyme).
abstract: Genzyme General is developing recombinant human alpha-glucosidase, produced in mammalian cell culture, as a potential treatment for Pompe disease. By July 2004, enrollment was completed in two clinical trials and an observational study in adults. Genzyme was planning to file for regulatory approval in Europe during 2004, followed by filings in the US and Japan in mid-2005.
authors.affiliation: University of Cambridge, Department of Medicine, Box 157, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. rhl20@cam.ac.uk
authors.forename: Robin H
authors.initials: RH
authors.lastname: Lachmann
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D011994:Recombinant Proteins / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D016896:Treatment Outcome; D000520:alpha-Glucosidases / Q000737:chemistry / Q000172:deficiency / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D000520:alpha-Glucosidases